Effect of Garlic Extracts on Changes in Cerebral Blood Flow

NCT05349253 | Completed

• 1 other identifier: 04-2020-036
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to assess the safety and efficacy of Garlic extracts for improving of cerebral blood flow.

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

• Change of Cerebral blood flow

  Regional cerebral blood flow is checked using Single Photon Emission Computed Tomography(SPECT)

  Change of Cerebral blood flow before and after 60 minutes garlic extract intake basis in the experimental group

Study Arms (2)

Garlic extracts

EXPERIMENTAL

Take 450mg of Garlic extracts(Food Item Making Report Product Name: Vegetable Extract Powder No. 1905, Item Report No.: 202004980275)

Dietary Supplement: Garlic extracts

placebo

PLACEBO COMPARATOR

As a food ingredient that does not affect blood pressure and is harmless to the human body, it is made almost identical in weight and appearance to garlic extract.

Dietary Supplement: Placebo

Interventions

Garlic extracts DIETARY_SUPPLEMENT

One intake in total

Garlic extracts

Placebo DIETARY_SUPPLEMENT

One intake in total

placebo

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy adults 19 years of age or older as of the screening date
• Those with no history of treatment for hypertension within the last 3 months
• A person who voluntarily decides to participate and agrees in writing to abide by the precautions after hearing and fully understanding the detailed explanation of this study

You may not qualify if:

• Those with systolic blood pressure of 160 mmHg or higher or diastolic blood pressure of 100 mmHg or higher
• Those who have had a stroke, myocardial infarction, percutaneous coronary angioplasty or surgery for coronary angioplasty within the past 6 months
• Persons with acute and severe cardiovascular diseases such as heart failure, myocardial infarction, and stroke
• Those with acute/chronic inflammation such as cancer, rheumatic disease, autoimmune disease, gastrointestinal disease, etc.
• Those who have a history of gastrointestinal diseases (eg Crohn's disease) or gastrointestinal surgery (except simple appendicectomy or hernia surgery) that may affect the absorption of the product for human application testing
• Persons who have taken prohibited concomitant drugs within the last 3 months
• Persons with a history of clinically significant hypersensitivity reactions to drugs and health functional foods
• Those who have received antipsychotic drug treatment within 2 months before the screening test
• Persons with a history of drug or alcohol abuse
• Pregnant or lactating women
• When women of childbearing potential of childbearing potential do not accept the implementation of appropriate contraceptive methods (except for women who have undergone sterilization)
• Subjects who have participated in health functional food related research or clinical trials within the last 3 months
• In case the principal investigator judges that it is not appropriate to participate in this study

Sponsors & Collaborators

• Pusan National University Yangsan Hospital: lead

Study Sites (1)

Pusan national university Yangsan Hospital

Gyeongsang, Yangsan, 50610, South Korea

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: June 9, 2021
• First Posted: April 27, 2022
• Study Start: October 27, 2020
• Primary Completion: March 31, 2021
• Study Completion: March 31, 2021
• Last Updated: April 27, 2022

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)